Prukaloprid

Prukaloprid
(IUPAC) ime
	4-Amino-5-hloro-N-[1-(3-metoksipropil)piperidin-4-il]-2,3-dihidro-1-benzofuran-7-karboksamid
Klinički podaci
Robne marke	Resolor, Resotran
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	179474-81-8
ATC kod	A03AE04
PubChem	3052762
UNII	0A09IUW5TP
Hemijski podaci
Formula	C18H26ClN3O3
Mol. masa	367,870 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23) ; Key: ZPMNHBXQOOVQJL-UHFFFAOYSA-N
Farmakoinformacioni podaci
Licenca	EU EMEA:link
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Oralno

Prukaloprid (Resolor) je lek koji deluje kao selektivni agonist visokog afiniteta za 5-HT₄ receptor.^[3] On poboljšava umanjeni motilitet creva koji je tipičan za hroničnu konstipaciju, i proizvodi normalnije pražnjenje creva.^[4]^[5]^[6]^[7]^[8]^[9] Prukaloprid je odobren za upotrebu u Evropi 2009^[10] i u Kanadi (Resotran) 2011^[11], dok u SAD-u nije odobren. Ovaj lek se ispituje za moguću primenu u tretmanu hronične intestinalne pseudoopstrukcije.^[12]^[13]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Briejer, M. R.; Bosmans, J. P.; Van Daele, P.; Jurzak, M.; Heylen, L.; Leysen, J. E.; Prins, N. H.; Schuurkes, J. A. (2001). „The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound”. European Journal of Pharmacology 423 (1): 71–83. DOI:10.1016/S0014-2999(01)01087-1. PMID 11438309.
↑ Clinical Trials NCT00793247
↑ Emmanuel, A. V.; Kamm, M. A.; Roy, A. J.; Kerstens, R.; Vandeplassche, L. (2012). „Randomised clinical trial: The efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study”. Alimentary Pharmacology & Therapeutics 35 (1): 48–55. DOI:10.1111/j.1365-2036.2011.04907.x. PMID 22061077.
↑ Smart, C. J.; Ramesh, A. N. (2011). „The successful treatment of acute refractory pseudo-obstruction with Prucalopride”. Colorectal Disease: no. DOI:10.1111/j.1463-1318.2011.02929.x.
↑ Bouras, E. P.; Camilleri, M.; Burton, D. D.; McKinzie, S. (1999). „Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans”. Gut 44 (5): 682–686. DOI:10.1136/gut.44.5.682. PMC 1727485. PMID 10205205.
↑ Bouras, E. P.; Camilleri, M.; Burton, D. D.; Thomforde, G.; McKinzie, S.; Zinsmeister, A. R. (2001). „Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder”. Gastroenterology 120 (2): 354–360. DOI:10.1053/gast.2001.21166. PMID 11159875.
↑ Tack, J.; Van Outryve, M.; Beyens, G.; Kerstens, R.; Vandeplassche, L. (2008). „Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives”. Gut 58 (3): 357–365. DOI:10.1136/gut.2008.162404. PMID 18987031.
↑ „European Medicines Agency -EPAR”. Arhivirano iz originala na datum 2010-01-31. Pristupljeno 2014-04-05.
↑ „Health Canada, Notice of Decision for Resotran”. Arhivirano iz originala na datum 2016-05-23. Pristupljeno 2014-04-05.
↑ Briejer, M. R.; Prins, N. H.; Schuurkes, J. A. (2001). „Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs”. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 13 (5): 465–472. DOI:10.1046/j.1365-2982.2001.00280.x. PMID 11696108.
↑ Oustamanolakis, P.; Tack, J. (2012). „Prucalopride for chronic intestinal pseudo-obstruction”. Alimentary Pharmacology & Therapeutics 35 (3): 398. DOI:10.1111/j.1365-2036.2011.04947.x.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Resolor (prucalopride)- Movetis Arhivirano 2010-03-16 na Wayback Machine-u

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[Briejer-3] Briejer, M. R.; Bosmans, J. P.; Van Daele, P.; Jurzak, M.; Heylen, L.; Leysen, J. E.; Prins, N. H.; Schuurkes, J. A. (2001). „The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound”. European Journal of Pharmacology 423 (1): 71–83. DOI:10.1016/S0014-2999(01)01087-1. PMID 11438309.

[4] Clinical Trials NCT00793247

[5] Emmanuel, A. V.; Kamm, M. A.; Roy, A. J.; Kerstens, R.; Vandeplassche, L. (2012). „Randomised clinical trial: The efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study”. Alimentary Pharmacology & Therapeutics 35 (1): 48–55. DOI:10.1111/j.1365-2036.2011.04907.x. PMID 22061077.

[6] Smart, C. J.; Ramesh, A. N. (2011). „The successful treatment of acute refractory pseudo-obstruction with Prucalopride”. Colorectal Disease: no. DOI:10.1111/j.1463-1318.2011.02929.x.

[7] Bouras, E. P.; Camilleri, M.; Burton, D. D.; McKinzie, S. (1999). „Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans”. Gut 44 (5): 682–686. DOI:10.1136/gut.44.5.682. PMC 1727485. PMID 10205205.

[8] Bouras, E. P.; Camilleri, M.; Burton, D. D.; Thomforde, G.; McKinzie, S.; Zinsmeister, A. R. (2001). „Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder”. Gastroenterology 120 (2): 354–360. DOI:10.1053/gast.2001.21166. PMID 11159875.

[Tack-9] Tack, J.; Van Outryve, M.; Beyens, G.; Kerstens, R.; Vandeplassche, L. (2008). „Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives”. Gut 58 (3): 357–365. DOI:10.1136/gut.2008.162404. PMID 18987031.

[10] „European Medicines Agency -EPAR”. Arhivirano iz originala na datum 2010-01-31. Pristupljeno 2014-04-05.

[11] „Health Canada, Notice of Decision for Resotran”. Arhivirano iz originala na datum 2016-05-23. Pristupljeno 2014-04-05.

[12] Briejer, M. R.; Prins, N. H.; Schuurkes, J. A. (2001). „Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs”. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 13 (5): 465–472. DOI:10.1046/j.1365-2982.2001.00280.x. PMID 11696108.

[13] Oustamanolakis, P.; Tack, J. (2012). „Prucalopride for chronic intestinal pseudo-obstruction”. Alimentary Pharmacology & Therapeutics 35 (3): 398. DOI:10.1111/j.1365-2036.2011.04947.x.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]